Advance of synergism of immune checkpoint blockade and anti-angiogenesis in cancer treatment
10.3969/j.issn.1001-1978.2021.02.006
- Author:
Wei-Wei ZHENG
1
;
Cheng QIAN
1
;
Wei ZOU
1
;
Chun-Mei YANG
1
;
Shan ZHANG
1
;
Ai-Yun WANG
1
;
Yin LU
1
;
Yuan-Yuan WU
1
;
Yin LU
2
;
Yuan-Yuan WU
2
Author Information
1. School of Pharmacy, Jiangsu Key lab for Pharmacology and Safely Evaluation of Chinese Materia Medica
2. Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine
- Publication Type:Journal Article
- Keywords:
blood vessel normalization;
CTLA4;
ICI;
PD-1;
TKI;
tumor immune microenvironment;
VEGF
- From:
Chinese Pharmacological Bulletin
2021;37(2):175-179
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitor ( ICI) activates the host' s anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induce tumor regression in a subset of advanced cancer patients. Anti-angiogenesis drugs commonly used to block tumor angiogenesis can inhibit the growth of tumors, but they cannot improve the survival of patients with limitations in application such as drug resistance. Tumor immune response is closely related to angiogenesis. In turn, tumor angiogenesis highly depends on immunosuppressive microenvironment. Recent studies have indicated that ICI resistance could be alleviated by combination therapy with anti-angiogenesis treatment, and the efficacy of combination therapy was superior to that of monotherapy. The reciprocal regulation between tumor vascular normalization and immune reprogramming forms a reinforcing loop that reconditions the tumor immune microenvironment to induce durable antitumor immunity. This review clarifies the latest understanding of ICI combined anti-angiogenesis therapy and provides ideas for subsequent research.
